CriticalAtypical antipsychotic of the benzamide class×Prokinetic, peripheral dopamine D2 receptor antagonist
Updated · Methodology
Mechanism
Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day and with QT-prolonging drugs (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Amisulpride also prolongs the QT interval, more so at higher doses and blood levels (intravenous amisulpride label, US Food and Drug Administration, FDA), and the Spanish SmPC for amisulpride tablets gives QT prolongation a warning of its own (amisulpride SmPC, AEMPS). The Spanish domperidone SmPC explains that such combinations are contraindicated because pharmacodynamic or pharmacokinetic interactions raise the risk of QT prolongation (AEMPS). The two drugs leave the body by different routes. The liver metabolises domperidone mainly through CYP3A4, while the body metabolises little amisulpride, and it leaves unchanged in the urine (domperidone and amisulpride SmPCs, AEMPS). The documents give no data on either drug changing the level of the other.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With domperidone, QT prolongation and torsade de pointes have been reported very rarely (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With amisulpride, QT prolongation, torsade de pointes, ventricular tachycardia, ventricular fibrillation, cardiac arrest and sudden death have been reported rarely (amisulpride SmPC, AEMPS). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and lists certain antipsychotics among them (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to its own documents, amisulpride belongs to this group. The US label states that it prolongs the QT interval more at higher doses and concentrations, and the Spanish SmPC gives QT prolongation a separate warning (amisulpride label, US Food and Drug Administration, FDA, and amisulpride SmPC, AEMPS). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances and heart disease such as congestive heart failure (domperidone SmPC, AEMPS). Prescribe amisulpride with caution in known cardiovascular disease or a family history of QT prolongation (amisulpride SmPC, AEMPS). The domperidone SmPC limits treatment to the lowest effective dose, no more than 30 mg a day, usually for no longer than a week (domperidone SmPC, AEMPS). If domperidone and amisulpride have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (domperidone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Amisulprida (nº registro 63996), sección 4.4 (2026)– AEMPS, CIMA, nº registro 63996 (Solian 400 mg), revisión 09/2026, secciones 4.3, 4.4, 4.5, 4.8 y 5.1
- FDA: Barhemsys (amisulpride) injection prescribing information (2026)– FDA, DailyMed setid ab23bc6e-b6a8-165f-e053-2a95a90ab144 (Acacia Pharma), revisión 06/2026 (versión 8), secciones 2.1, 5.1, 7.2 y 12.2; forma intravenosa en dosis única de 5–10 mg